Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 23, 2021 2:43pm
173 Views
Post# 33908541

RE:RE:RE:RE:RE:RE:Volume just skyrocketed

RE:RE:RE:RE:RE:RE:Volume just skyrocketedI was surprisedd by that big of a reaction. Even I have evidently underestimated the retail impact but Scarlett probably would have seen this coming. 

I am sure the sourt in buying interest will settle down as the minutes pass but it is likely in the algos hands now for the rest of the day. The people who bought based on what he said will likely hold onto it for a while and see how the cancer trial data looks. 

Wino115 wrote: Of course, the big question is how much of this will hold on for a month or two.  Likely only a bit, but it's nice!


Wino115 wrote: I saw it.  It was very brief but he did a good job stating it's a hidden gem and spoke about  cancer only. 

SPCEO1 wrote: What an incredibly crazy stock market we have now. This is beccause of my friend recommending the stock on Fox Business News. I did not have a chance to watch it but he must have sold the story well.

Maybe this will finally convince TH that paying attention to the retail investor pays dividends.

JasontheGreat wrote: Whoa! Is this on any news?

 

 




<< Previous
Bullboard Posts
Next >>